R. Glenn Hammonds
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
R. Glenn Hammonds has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Choh Hao Li
Donald Yamashiro, Claudia M. Cabrera, and Manfred Westphal Laboratory of Molecular Endocrinology , University of California, San Francisco , San Francisco, California, 94143
10 shared publicationsC H Li
8 shared publicationsDavid Puett
Department of Biochemistry, Vanderbilt University, Nashville, TN 37232 USA
4 shared publicationsManfred Westphal
Laboratory of Molecular Endocrinology Brain Tumor Research Center, University of Calitornia, San Francisco, San Francisco, California 94143 USA
4 shared publicationsP Nicolas
Laboratory of Molecular Endocrinology, University of California, San Francisco, CA 94143
4 shared publicationsDonald Yamashiro
Laboratory of Molecular Endocrinology University of California San Francisco, CA 94143, USA
3 shared publications
Latest Publications
- Open Access
- 1 April 1996
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 271 (16) , 9785-9789
Characterization of Gas6, a Member of the Superfamily of G Domain-containing Proteins, as a Ligand for Rse and Axl
- 1 April 1996
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 271 (16) , 9785-9789
Open AccessCharacterization of Gas6, a Member of the Superfamily of G Domain-containing Proteins, as a Ligand for Rse and Axl
- Open Access
- 15 March 1996
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 16 (6) , 2012-2019
Identification of Gas6 as a growth factor for human Schwann cells
Schwann cells are one of the principal components of the peripheral nervous system. They play a crucial role in nerve regeneration and can be used clinically in the repair of injured nerves. We have established serum-free, defined culture conditions that rapidly expand adult human Schwann cells without fibroblast growth. We find that Gas6, a ligand for the Axl and Rse/Tyro3 receptor protein tyrosine kinase family, stimulates human Schwann cell growth, increasing both cell number and thymidine incorporation. Gas6 has synergistic effects with the other known human Schwann cell mitogens, heregulin/glial growth factor and forskolin. Addition of Gas6 causes phosphorylation of Axl and Rse/Tyro3 simultaneously and results in ERK-2 activation. A combination of Gas6 with heregulin and forskolin, on a defined background, supports maximal Schwann cell proliferation, while preserving the typical Schwann cell morphology and expression of the Schwann cell markers S-100, glial fibrillary acidic protein, and low-affinity nerve growth factor receptor. Gas6 mRNA is present in both spinal motor neurons and large neurons of the dorsal root ganglia, and neural injury has been reported to upregulate Rse/Axl in the schwann cell. This is the first demonstration of a potentially important biological role for the human Gas6/Rse-Axl system.
- 15 March 1996
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 16 (6) , 2012-2019
Open AccessIdentification of Gas6 as a growth factor for human Schwann cells
Schwann cells are one of the principal components of the peripheral nervous system. They play a crucial role in nerve regeneration and can be used clinically in the repair of injured nerves. We have established serum-free, defined culture conditions that rapidly expand adult human Schwann cells without fibroblast growth. We find that Gas6, a ligand for the Axl and Rse/Tyro3 receptor protein tyrosine kinase family, stimulates human Schwann cell growth, increasing both cell number and thymidine incorporation. Gas6 has synergistic effects with the other known human Schwann cell mitogens, heregulin/glial growth factor and forskolin. Addition of Gas6 causes phosphorylation of Axl and Rse/Tyro3 simultaneously and results in ERK-2 activation. A combination of Gas6 with heregulin and forskolin, on a defined background, supports maximal Schwann cell proliferation, while preserving the typical Schwann cell morphology and expression of the Schwann cell markers S-100, glial fibrillary acidic protein, and low-affinity nerve growth factor receptor. Gas6 mRNA is present in both spinal motor neurons and large neurons of the dorsal root ganglia, and neural injury has been reported to upregulate Rse/Axl in the schwann cell. This is the first demonstration of a potentially important biological role for the human Gas6/Rse-Axl system.
- 1 December 1995
- Published by The Endocrine Society in Endocrinology
- Vol. 136 (12) , 5694-5699
In vitro characterization of four novel classes of growth hormone-releasing peptide.
Reexamination of the hexapeptide GH-releasing peptide (GHRP-6) structure/function has lead to the development of four novel classes of compound that stimulate GH release. Each class is represented as follows: a pentapeptide, G-7039; a tetrapeptide, G-7134; a pseudotripeptide, G-7502; and a rigid cyclic heptapeptide, G-7203. The EC50 values for these compounds, determined by GH dose-response curves using primary cultures of rat pituitary cells, were 0.18, 0.34, 10.6, and 0.43 nM, respectively. To demonstrate that these compounds were acting at the putative GHRP receptor, challenges were made using combinations that included GHRP-6 and GH-releasing hormone (GHRH). All four new classes further increased GH release in combination with GHRH, but not with GHRP-6. Homologous desensitization occurred after 45 min of exposure to the new compounds while the cells remained sensitive to GHRH. Somatostatin inhibited all of these compounds. Additionally, G-7039 elevated free calcium, as occurs with GHRP-6. All four classes elicited a robust GH release, a small increase in PRL, and no change in LH, FSH, ACTH, or TSH. We conclude that these novel compounds are potent and direct stimulators of pituitary GH release, with in vitro attributes that suggest mediation via a specific GHRP-like mechanism.
- 1 December 1995
- Published by The Endocrine Society in Endocrinology
- Vol. 136 (12) , 5694-5699
In vitro characterization of four novel classes of growth hormone-releasing peptide.
Reexamination of the hexapeptide GH-releasing peptide (GHRP-6) structure/function has lead to the development of four novel classes of compound that stimulate GH release. Each class is represented as follows: a pentapeptide, G-7039; a tetrapeptide, G-7134; a pseudotripeptide, G-7502; and a rigid cyclic heptapeptide, G-7203. The EC50 values for these compounds, determined by GH dose-response curves using primary cultures of rat pituitary cells, were 0.18, 0.34, 10.6, and 0.43 nM, respectively. To demonstrate that these compounds were acting at the putative GHRP receptor, challenges were made using combinations that included GHRP-6 and GH-releasing hormone (GHRH). All four new classes further increased GH release in combination with GHRH, but not with GHRP-6. Homologous desensitization occurred after 45 min of exposure to the new compounds while the cells remained sensitive to GHRH. Somatostatin inhibited all of these compounds. Additionally, G-7039 elevated free calcium, as occurs with GHRP-6. All four classes elicited a robust GH release, a small increase in PRL, and no change in LH, FSH, ACTH, or TSH. We conclude that these novel compounds are potent and direct stimulators of pituitary GH release, with in vitro attributes that suggest mediation via a specific GHRP-like mechanism.
- 21 November 1995
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 92 (24) , 11165-11169
Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.
Another class of growth hormone (GH) secretagogues has been discovered by altering the backbone structure of a flexible linear GH-releasing peptide (GHRP). In vitro and in vivo characterization confirms these GH secretagogues as the most potent and smallest (M(r) < 500) reported. Anabolic efficacy is demonstrated in rodents with intermittent delivery. A convergent model of the bioactive conformation of GHRPs is developed and is supported by the NMR structure of a highly potent cyclic analog of GHRP-2. The model and functional data provide a logical framework for the further design of low-molecular weight secretagogues and illustrate the utility of an interdisciplinary approach to elucidating potential bound-state conformations of flexible peptide ligands.
- 21 November 1995
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 92 (24) , 11165-11169
Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.
Another class of growth hormone (GH) secretagogues has been discovered by altering the backbone structure of a flexible linear GH-releasing peptide (GHRP). In vitro and in vivo characterization confirms these GH secretagogues as the most potent and smallest (M(r) < 500) reported. Anabolic efficacy is demonstrated in rodents with intermittent delivery. A convergent model of the bioactive conformation of GHRPs is developed and is supported by the NMR structure of a highly potent cyclic analog of GHRP-2. The model and functional data provide a logical framework for the further design of low-molecular weight secretagogues and illustrate the utility of an interdisciplinary approach to elucidating potential bound-state conformations of flexible peptide ligands.
- Open Access
- 1 March 1994
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 9 (3) , 381-387
Effects of kistrin on bone resorption in vitro and serum calcium in vivo
In many cell systems, cell-cell and cell-matrix interactions are mediated by integrins, a family of cell surface heterodimeric glycoprotein receptors. Osteoclast integrins may play a role in the process of bone resorption. Osteoclasts express the αv and β3 subunits of the vitronectin receptor and adhere to a wide range of proteins in vitro, all of which contain the amino acid sequence Arg-Gly-Asp (RGD), an adhesion site recognition sequence common to many protein ligands that bind to integrins. The effect of kistrin, an RGD-containing snake venom protein, on osteoclast-mediated bone resorption was investigated in vivo and in vitro. When kistrin was infused into normocalcemic and hypercalcemic mice, serum calcium was significantly lowered at 3 and 6 h after the start of infusion, indicating an inhibitory effect on osteoclast activity in vivo. In vitro, kistrin potently inhibited bone resorption by isolated rat osteoclasts cultured on slices of bovine bone, and kistrin also inhibited the attachment of 293 cells expressing recombinant human αvβ3 to fibrinogen (IC50 = 1 nM). These results indicate the potential therapeutic use of RGD-containing molecules for hypercalcemia of malignancy or for other disorders associated with bone loss.
- 1 March 1994
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 9 (3) , 381-387
Open AccessEffects of kistrin on bone resorption in vitro and serum calcium in vivo
In many cell systems, cell-cell and cell-matrix interactions are mediated by integrins, a family of cell surface heterodimeric glycoprotein receptors. Osteoclast integrins may play a role in the process of bone resorption. Osteoclasts express the αv and β3 subunits of the vitronectin receptor and adhere to a wide range of proteins in vitro, all of which contain the amino acid sequence Arg-Gly-Asp (RGD), an adhesion site recognition sequence common to many protein ligands that bind to integrins. The effect of kistrin, an RGD-containing snake venom protein, on osteoclast-mediated bone resorption was investigated in vivo and in vitro. When kistrin was infused into normocalcemic and hypercalcemic mice, serum calcium was significantly lowered at 3 and 6 h after the start of infusion, indicating an inhibitory effect on osteoclast activity in vivo. In vitro, kistrin potently inhibited bone resorption by isolated rat osteoclasts cultured on slices of bovine bone, and kistrin also inhibited the attachment of 293 cells expressing recombinant human αvβ3 to fibrinogen (IC50 = 1 nM). These results indicate the potential therapeutic use of RGD-containing molecules for hypercalcemia of malignancy or for other disorders associated with bone loss.
- 1 April 1993
- Published by Wiley in Journal of Cellular Physiology
- Vol. 155 (1) , 112-119
Differential effects of transforming growth factor‐β1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts
Transforming growth factor‐β (TGF‐β) and bone morphogenetic protein 4 (BMP 4) are both able, under certain circumstances, to induce endochondral bone formation in vivo. This study compared the effects of TGF‐β and BMP 4 on the gene expression of a retinoic acid (RA) responsive rat clonal preosteoblast cell line, UMR 201, as well as the way in which these proteins interact with RA in these cells. Both similarities as well as differences between the effects and mechanism of action of TGF‐β1 and BMP 4 were demonstrated. TGF‐β1 (0.1 ng/ml) strongly induced matrix gla protein (MGP) mRNA and increased the steady state osteonectin (ON) mRNA level. Cotreatment with TGF‐β1 and RA did not result in a further increase in MGP mRNA expression. In contrast, BMP 4 alone had no influence on MGP or ON mRNA expression but it significantly enhanced the RA induction of MGP mRNA. Pro‐α(1) (l) collagen mRNA was increased by TGF‐β1 (1 ng/ml) and BMP 4 (50 ng/ml). The addition of either TGF‐β1 or BMP 4 together with RA resulted in a further increase in pro‐α1(l) collagen mRNA levels. Both RA and TGF‐β1, but not BMP 4, increased the transcriptional rate of the pro‐α 1(l) collagen gene. TGF‐β1 reduced the constitutive as well as RA‐induced expression of osteopontin (OP) mRNA while BMP 4 reduced only the constitutive expression of OP mRNA. RA increased the transcriptional rate of the OP gene. Since the responses of UMR 201 cells to these structurally related factors were not identical, the results lend support to the concept that the coordinated expression of members of the TGF‐β1 superfamily may be necessary to control the progression of specific cell types through their differentiation pathways.
- 1 April 1993
- Published by Wiley in Journal of Cellular Physiology
- Vol. 155 (1) , 112-119
Differential effects of transforming growth factor‐β1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts
Transforming growth factor‐β (TGF‐β) and bone morphogenetic protein 4 (BMP 4) are both able, under certain circumstances, to induce endochondral bone formation in vivo. This study compared the effects of TGF‐β and BMP 4 on the gene expression of a retinoic acid (RA) responsive rat clonal preosteoblast cell line, UMR 201, as well as the way in which these proteins interact with RA in these cells. Both similarities as well as differences between the effects and mechanism of action of TGF‐β1 and BMP 4 were demonstrated. TGF‐β1 (0.1 ng/ml) strongly induced matrix gla protein (MGP) mRNA and increased the steady state osteonectin (ON) mRNA level. Cotreatment with TGF‐β1 and RA did not result in a further increase in MGP mRNA expression. In contrast, BMP 4 alone had no influence on MGP or ON mRNA expression but it significantly enhanced the RA induction of MGP mRNA. Pro‐α(1) (l) collagen mRNA was increased by TGF‐β1 (1 ng/ml) and BMP 4 (50 ng/ml). The addition of either TGF‐β1 or BMP 4 together with RA resulted in a further increase in pro‐α1(l) collagen mRNA levels. Both RA and TGF‐β1, but not BMP 4, increased the transcriptional rate of the pro‐α 1(l) collagen gene. TGF‐β1 reduced the constitutive as well as RA‐induced expression of osteopontin (OP) mRNA while BMP 4 reduced only the constitutive expression of OP mRNA. RA increased the transcriptional rate of the OP gene. Since the responses of UMR 201 cells to these structurally related factors were not identical, the results lend support to the concept that the coordinated expression of members of the TGF‐β1 superfamily may be necessary to control the progression of specific cell types through their differentiation pathways.
- 1 December 1991
- Published by The Endocrine Society in Endocrinology
- Vol. 129 (6) , 3424-3426
A POTENT INHIBITOR OF OSTEOCLASTIC BONE RESORPTION WITHIN A HIGHLY CONSERVED PENTAPEPTIDE REGION OF PARATHYROID HORMONE-RELATED PROTEIN; PTHrP[107–lll]
We have recently shown that a carboxyl-terminal sequence of parathyroid hormone-related protein, PTHrP[107-139], is a potent direct inhibitor of osteoclastic bone resorption. We now report that this bone resorption inhibitory activity, which we have called osteostatin, is entirely contained within the highly conserved pentapeptide PTHrP[107-111]. Our results indicate that processing at residue 106 and a free amino terminus is required for full activity of the peptide. The retroinverted peptide is considerably less potent than the parent peptide. The retention of full biological activity in such a short fragment was unexpected. This data provides the basis for the development of further analogs with potential therapeutic use in disorders associated with increased osteoclastic bone resorption.
- 1 December 1991
- Published by The Endocrine Society in Endocrinology
- Vol. 129 (6) , 3424-3426
A POTENT INHIBITOR OF OSTEOCLASTIC BONE RESORPTION WITHIN A HIGHLY CONSERVED PENTAPEPTIDE REGION OF PARATHYROID HORMONE-RELATED PROTEIN; PTHrP[107–lll]
We have recently shown that a carboxyl-terminal sequence of parathyroid hormone-related protein, PTHrP[107-139], is a potent direct inhibitor of osteoclastic bone resorption. We now report that this bone resorption inhibitory activity, which we have called osteostatin, is entirely contained within the highly conserved pentapeptide PTHrP[107-111]. Our results indicate that processing at residue 106 and a free amino terminus is required for full activity of the peptide. The retroinverted peptide is considerably less potent than the parent peptide. The retention of full biological activity in such a short fragment was unexpected. This data provides the basis for the development of further analogs with potential therapeutic use in disorders associated with increased osteoclastic bone resorption.
- 1 December 1991
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 6 (12) , 1387-1393
Bone morphogenetic protein-2b stimulation of growth and osteogenic phenotypes in rat osteoblast-like cells: Comparison with TGF-β1
The biologic effects of recombinant human bone morphogenetic protein‐2b (BMP‐2b = BMP‐4) were studied and compared with transforming growth factor‐β1 (TGF‐β1) in fetal rat osteoblast‐like (ROB) cells. Similar to the effects of TGF‐β1, BMP‐2b stimulated DNA and collagen synthesis as well as protein accumulation. Unlike TGF‐β1, which inhibited alkaline phosphatase activity, BMP‐2b enhanced enzyme activity eight‐to ninefold over the control level. The present study demonstrates direct actions of BMP‐2b on bone‐associated cells to stimulate osteogenic phenotypes in vitro and provides a cellular mechanism for the induction of bone formation by BMP‐2b in vivo.
- 1 December 1991
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 6 (12) , 1387-1393
Bone morphogenetic protein-2b stimulation of growth and osteogenic phenotypes in rat osteoblast-like cells: Comparison with TGF-β1
The biologic effects of recombinant human bone morphogenetic protein‐2b (BMP‐2b = BMP‐4) were studied and compared with transforming growth factor‐β1 (TGF‐β1) in fetal rat osteoblast‐like (ROB) cells. Similar to the effects of TGF‐β1, BMP‐2b stimulated DNA and collagen synthesis as well as protein accumulation. Unlike TGF‐β1, which inhibited alkaline phosphatase activity, BMP‐2b enhanced enzyme activity eight‐to ninefold over the control level. The present study demonstrates direct actions of BMP‐2b on bone‐associated cells to stimulate osteogenic phenotypes in vitro and provides a cellular mechanism for the induction of bone formation by BMP‐2b in vivo.
- 1 July 1991
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 6 (7) , 767-777
Retinoic acid modulation of mrna levels in malignant, nontransformed, and immortalized osteoblasts
Clonal cell lines presumably “arrested” at a particular stage of differentiation are useful models to study the processes of differentiation in osteoblasts. UMR‐201 is a presumptive preosteoblastic nontransformed rat clonal cell line with a limited life span in culture. Two immortalized cell lines, UMR‐201‐10A (10A) and UMR‐201‐10B (10B), were derived from UMR‐201 by stable transfection with simian virus (SV) 40 large T antigen. This study compares the growth and profile of gene expression of the immortalized cell lines with those of UMR‐201 and UMR‐106‐06, a rat clonal cell line with well‐defined osteoblast‐like phenotypic characteristics. All four cell lines constitutively expressed the mRNA for the γ, α, and β receptors for retinoic acid (RA), the growth hormone receptor, pro‐α1(I) collagen, osteonectin, bone proteoglycan I, and bone morphogenetic proteins (BMP) 1 and 2A. Alkaline phosphatase mRNA was absent in the preosteoblast cell lines but was induced by treatment with 10−6 M RA, which also increased the steady‐state levels of mRNA for osteopontin and BMP1. mRNA for matrix gla protein was constitutively present and further induced by RA in UMR‐201 and 10B only. Messenger RNA for bone sialoprotein and bone morphogenetic protein 3 were constitutively expressed in UMR‐106‐06 and UMR‐201 but absent in the immortalized cell lines. None of the cell lines expressed measurable mRNA for bone gla protein or bone proteoglycan II. 10B grew more rapidly than UMR‐201, but unlike UMR‐201, it was also able to proliferate in serum‐free medium and exhibit anchorage‐independent growth. In summary, this study identifies novel retinoic acid effects on gene expression in these cells. Differences noted in the expression of mRNAs between UMR‐106‐06 and the other cell lines may provide some insight into the sequence of expression of these phenotypic characteristics as osteoblasts differentiate.
- 1 July 1991
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 6 (7) , 767-777
Retinoic acid modulation of mrna levels in malignant, nontransformed, and immortalized osteoblasts
Clonal cell lines presumably “arrested” at a particular stage of differentiation are useful models to study the processes of differentiation in osteoblasts. UMR‐201 is a presumptive preosteoblastic nontransformed rat clonal cell line with a limited life span in culture. Two immortalized cell lines, UMR‐201‐10A (10A) and UMR‐201‐10B (10B), were derived from UMR‐201 by stable transfection with simian virus (SV) 40 large T antigen. This study compares the growth and profile of gene expression of the immortalized cell lines with those of UMR‐201 and UMR‐106‐06, a rat clonal cell line with well‐defined osteoblast‐like phenotypic characteristics. All four cell lines constitutively expressed the mRNA for the γ, α, and β receptors for retinoic acid (RA), the growth hormone receptor, pro‐α1(I) collagen, osteonectin, bone proteoglycan I, and bone morphogenetic proteins (BMP) 1 and 2A. Alkaline phosphatase mRNA was absent in the preosteoblast cell lines but was induced by treatment with 10−6 M RA, which also increased the steady‐state levels of mRNA for osteopontin and BMP1. mRNA for matrix gla protein was constitutively present and further induced by RA in UMR‐201 and 10B only. Messenger RNA for bone sialoprotein and bone morphogenetic protein 3 were constitutively expressed in UMR‐106‐06 and UMR‐201 but absent in the immortalized cell lines. None of the cell lines expressed measurable mRNA for bone gla protein or bone proteoglycan II. 10B grew more rapidly than UMR‐201, but unlike UMR‐201, it was also able to proliferate in serum‐free medium and exhibit anchorage‐independent growth. In summary, this study identifies novel retinoic acid effects on gene expression in these cells. Differences noted in the expression of mRNAs between UMR‐106‐06 and the other cell lines may provide some insight into the sequence of expression of these phenotypic characteristics as osteoblasts differentiate.